Get the Stockscreener App
89.02
0.36%
-0.325
After Hours:
89.02
0.005
+0.01%
Vaxcyte Inc stock is traded at $89.02, with a volume of 752.27K.
It is down -0.36% in the last 24 hours and up +3.52% over the past month.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
See More
Previous Close:
$89.34
Open:
$89.09
24h Volume:
752.27K
Relative Volume:
0.63
Market Cap:
$11.09B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-19.35
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-3.19%
1M Performance:
+3.52%
6M Performance:
+20.40%
1Y Performance:
+18.96%
1-Day Range:
$87.86
$91.02
1-Week Range:
$83.59
$91.86
52-Week Range:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
89.02 | 11.09B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 - Yahoo Finance
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants - Clinical Trials Arena
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Calamos Advisors LLC - MarketBeat
Vaxcyte COO Jim Wassil sells $689,790 in stock - MSN
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage - Marketscreener.com
Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells 8,000 Shares of Stock - MarketBeat
Vaxcyte advances to final stage in infant vaccine study - MSN
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study - GlobeNewswire
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention - The Bakersfield Californian
Revolutionary Pneumococcal Vaccine Shows Promise: Vaxcyte's VAX-31 Hits Major Clinical Milestone - StockTitan
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Vaxcyte COO Jim Wassil sells $689,790 in stock By Investing.com - Investing.com Australia
Jennison Associates LLC Buys 9,121 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Vaccine Innovator Vaxcyte Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - GlobeNewswire Inc.
Nisa Investment Advisors LLC Raises Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
(PCVX) Proactive Strategies - Stock Traders Daily
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Brokers Set Expectations for Vaxcyte FY2025 Earnings - Defense World
Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Cantor Fitzgerald Predicts Vaxcyte FY2025 Earnings - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 By Investing.com - Investing.com South Africa
CARGO Therapeutics, Inc. Enters into Sublease Agreement with Vaxcyte, Inc -July 08, 2024 at 04:18 pm EDT - Marketscreener.com
Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market - MSN
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Trading Up 7.8%Should You Buy? - MarketBeat
Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Alexandria Announces Long-Term Lease at San Carlos Mega Campus - MSN
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte (NASDAQ:PCVX) Stock Price Up 7.8%Here's What Happened - MarketBeat
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy (NASDAQ:PCVX) - Seeking Alpha
Why Vaxcyte Shares Are Attracting Attention - TipRanks
Leerink Partnrs Forecasts Vaxcyte FY2029 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Diversified Trust Co Acquires New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock By Investing.com - Investing.com Australia
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock - Investing.com India
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - The Malaysian Reserve
Long Term Trading Analysis for (PCVX) - Stock Traders Daily
Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $145.71 - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 By Investing.com - Investing.com Australia
Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 - Investing.com
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):